NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
Provided By GlobeNewswire
Last update: Dec 10, 2024
-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p<0.0001) --
Read more at globenewswire.com19.75
-0.46 (-2.28%)
NASDAQ:NAMSW (6/16/2025, 8:00:01 PM)
9.54
+0.13 (+1.38%)
Find more stocks in the Stock Screener
NAMS Latest News and Analysis
8 days ago - ChartmillGet insights into the top gainers and losers of Monday's pre-market session.The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
